Citation Impact
Citing Papers
Colorectal cancer statistics, 2023
2023 Standout
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study
2014
TEER Measurement Techniques for In Vitro Barrier Model Systems
2015 Standout
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
2020 Standout
Investigation of serotonin type 4 receptor expression in human and non-human primate gastrointestinal samples
2006
Pharmacokinetics and Safety of Golimumab, a Fully Human Anti‐TNF‐α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis
2007
Functional Bowel Disorders
2006 Standout
Top 10 Challenges in Cancer Immunotherapy
2020
Honey, Propolis, and Royal Jelly: A Comprehensive Review of Their Biological Actions and Health Benefits
2017 Standout
From tumour heterogeneity to advances in precision treatment of colorectal cancer
2016
Gastrointestinal dysfunction in Parkinson's disease
2003 Standout
Functional Gastroduodenal Disorders
2006 Standout
Bowel Disorders
2016 Standout
Molecular, pharmacological and functional diversity of 5-HT receptors
2002 Standout
Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome
2005
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis
2015
Melanin Pigmentation in Mammalian Skin and Its Hormonal Regulation
2004 Standout
Basic and clinical pharmacology of new motility promoting agents
2005
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Modulation of Intestinal Gas Dynamics in Healthy Human Volunteers by the 5-HT4Receptor Agonist Tegaserod
2006
Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population
2016
Emerging drugs for irritable bowel syndrome
2006
Systematic Review on the Management of Chronic Constipation in North America
2005
Tegaserod, a 5‐HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects
2003
The human epidermis models EpiSkin®, SkinEthic® and EpiDerm®: An evaluation of morphology and their suitability for testing phototoxicity, irritancy, corrosivity, and substance transport
2005
Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome
2008 Standout
Pathophysiology and treatment of functional dyspepsia
2004
Physiological Modulation of Intestinal Motility by Enteric Dopaminergic Neurons and the D2Receptor: Analysis of Dopamine Receptor Expression, Location, Development, and Function in Wild-Type and Knock-Out Mice
2006
Wound Healing Dressings and Drug Delivery Systems: A Review
2007 Standout
Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation
2004
The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders
2007 Standout
Effects of mitemcinal (GM-611), an orally active erythromycin-derived prokinetic agent, on delayed gastric emptying and postprandial glucose in a new minipig model of diabetes
2008 StandoutNobel
Irritable bowel syndrome
2016 Standout
Colorectal cancer
2019 Standout
Effects of a 5‐HT4 receptor agonist on oesophageal function and gastro‐oesophageal reflux: studies using combined impedance‐manometry and combined impedance‐pH
2006
Serotoninergic neuroenteric modulators
2001
Effect of tegaserod in chronic constipation: A randomized, double-blind, controlled trial
2004
The Functional Gastrointestinal Disorders and the Rome III Process
2006 Standout
Pyroptosis: mechanisms and diseases
2021 Standout
Irritable Bowel Syndrome
2001
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
2011 Standout
Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications?
2002 Standout
Activation of peripheral 5‐HT4receptors attenuates colonic sensitivity to intraluminal distension
2005
MITEMCINAL (GM‐611), AN ORALLY ACTIVE MOTILIN RECEPTOR AGONIST, IMPROVES DELAYED GASTRIC EMPTYING IN A CANINE MODEL OF DIABETIC GASTROPARESIS
2008 StandoutNobel
The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high‐resolution manometry and videofluoroscopy
2006
Serotonin and GI clinical disorders
2008
Current understanding of the human microbiome
2018 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Regional gastric contractility alterations in a diabetic gastroparesis mouse model: effects of cholinergic and serotoninergic stimulation
2004
Tegaserod
2001
Influence of tegaserod on proximal gastric tone and on the perception of gastric distension
2003
An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome
2003
Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine
2014
Guidelines on the irritable bowel syndrome: mechanisms and practical management
2007
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
2014
Childhood Functional Gastrointestinal Disorders: Child/Adolescent
2006 Standout
Serotonin, tryptophan metabolism and the brain-gut-microbiome axis
2014 Standout
A randomized, double‐blind, placebo‐controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation
2002
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Management of Chronic Constipation in the Elderly
2008
End-to-end design of wearable sensors
2022 Standout
Lysosome-targeting chimaeras for degradation of extracellular proteins
2020 StandoutNatureNobel
Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis
2008 Standout
Effect of tegaserod on gut transit in male and female subjects
2005
Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway
2021 StandoutNobel
Functional dyspepsia: evaluation and treatment
2003
Toxicity and Antimicrobial Activity of a Hydrocolloid Dressing Containing Silver Particles in an ex vivo Model of Cutaneous Infection
2003
Management of glioblastoma: State of the art and future directions
2020 Standout
Diagnosis and Management of Rectal Cancer in Patients Younger Than 50 Years: Rising Global Incidence and Unique Challenges
2022
American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis
2004
Translational Applications of Hydrogels
2021
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies
2016
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
2018
Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation
2016
Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma
2016 StandoutNobel
Colorectal cancer statistics, 2017
2017 Standout
Effect of Tegaserod on Esophageal Pain Threshold, Regurgitation, and Symptom Relief in Patients With Functional Heartburn and Mechanical Sensitivity
2006
Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments
2010 Standout
Works of Stuart Osborne being referenced
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
2013
Tegaserod, a 5‐HT 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects
2001
A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN
2013
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
2013
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
2018
Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919)
2001
Effect of Meal Timing Not Critical for the Pharmacokinetics of Tegaserod (HTF 919)
1999
Predictivity of an in vitro model for acute and chronic skin irritation (SkinEthic) applied to the testing of topical vehicles
1999
Safeher: A Study of Assisted- and Self-Administered Subcutaneous Trastuzumab (H-SC) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (EBC)
2012
Abstract P4-12-11: Patient preference for subcutaneous trastuzumab via handheld syringe versus intravenous infusion in HER2-positive early breast cancer: Cohort 2 of the PrefHer study
2013